None
Quote | Turning Point Therapeutics Inc. (NYSE:TPTX)
Last: | $ |
---|---|
Change Percent: | 3.63% |
Open: | $63.94 |
Close: | $66.17 |
High: | $66.98 |
Low: | $63.94 |
Volume: | 369,785 |
Last Trade Date Time: | 02/12/2020 04:41:38 pm |
News | Turning Point Therapeutics Inc. (NYSE:TPTX)
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Turning Point Therapeutics press release ( NASDAQ: TPTX ): Q2 GAAP EPS of -$2.48 misses by $0.78 . Revenue of $0.12M (-97.7% Y/Y) misses by $2.15M . For further details see: Turning Point Therapeutics GAAP EPS of -$2.48 misses by $0.78, revenue of $0.12M ...
Message Board Posts | Turning Point Therapeutics Inc. (NYSE:TPTX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Turning Point Therapeutics Inc. Company Name:
TPTX Stock Symbol:
NYSE Market:
New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that consider...
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET...